Antiplatelet therapy to prevent thrombosis after hip fracture. Rationale for a randomised trial.

Documents similaires

• ANTIPLATELET THERAPY TO PREVENT THROMBOSIS AFTER HIP FRACTURE - REPLY
  par: Macmahon, S, et autres
  Publié: (1995)
• The pulmonary embolism prevention (PEP) trial: Effects of low-dose aspirin on major vascular events in patients with hip fracture
  par: Prentice, C, et autres
  Publié: (1999)
• Rationale and design of the ADAPT-TAVR trial: a randomised comparison of edoxaban and dual antiplatelet therapy for prevention of leaflet thrombosis and cerebral embolisation after transcatheter aortic valve replacement
  par: Kyung Won Kim, et autres
  Publié: (2021-01-01)
• Antiplatelet therapy for thromboprophylaxis: the need for careful consideration of the evidence from randomised trials. Antiplatelet Trialists' Collaboration.
  par: Collins, R, et autres
  Publié: (1994)
• A randomised controlled trial of antiplatelet therapy in combination with Rt-PA thrombolysis in ischemic stroke: rationale and design of the ARTIS-Trial
  par: de Haan RJ, et autres
  Publié: (2010-05-01)